Patents Examined by David Lukton
  • Methods and compositions for the detection of cancer
    Patent number: 8686112
    Abstract: A molecular probe for use in detection of cancer cells expressing an Ig superfamily cell adhesion molecule that binds in a homophilic fashion in a subject includes a targeting agent that specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of the Ig superfamily cell adhesion molecule.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: April 1, 2014
    Assignee: Case Western Reserve University
    Inventor: Susann Brady-Kalnay
  • Chimerical peptidic molecules with antiviral properties against the viruses of the Flaviviridae family
    Patent number: 8674063
    Abstract: The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: March 18, 2014
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martin Dunn, Noralvis Fleitas Salazar, Osmany Guirola Cruz, Patricia Gabriela Toledo Mayora, Mónica Sarría Núñez, Alexis Musacchio Lasa, Olvaldo Reyes Acosta, Hilda Elisa Garay Pérez, Anìa Cabrales Rico
  • Peptide pharmaceutical for oral delivery
    Patent number: 8664178
    Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: March 4, 2014
    Assignee: Enteris BioPharma, Inc.
    Inventors: William Stern, Angelo P. Consalvo
  • Peptide fragments for inducing synthesis of extracellular matrix proteins
    Patent number: 8658764
    Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: February 25, 2014
    Assignee: Helix Biomedix, Inc.
    Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
  • Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases
    Patent number: 8642729
    Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: February 4, 2014
    Assignee: Institut Pasteur
    Inventor: Catherine Rougeot
  • Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof
    Patent number: 8642545
    Abstract: What is provided is EPO mimetic peptide derivatives defined as formula (I) and their pharmaceutical salts, the preparation thereof, wherein R1, R2, R3, R4, R5, n1, n2 are defined as described in description. A composition comprising of an EPO mimetic peptide derivative defined as formula (I) and its pharmaceutical salt. The uses of the derivatives and their pharmaceutical salts, as well as the uses of the compositions described above in treatment of diseases characterized by a deficiency of EPO or a low or defective red blood cell population.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: February 4, 2014
    Assignee: Jiangsu Hansoh Pharmaceutical Co., Ltd
    Inventors: Aifeng Lü, Changan Sun, Tao Jiang, Wentao Wu, Yali Wang
  • C-terminal domain truncation of mGluR1? by calpain and uses thereof
    Patent number: 8642559
    Abstract: A composition comprising a peptide or a peptidomimetic thereof that inhibits the C-terminal domain truncation of mGluR1? by calpain, wherein the peptide is 10-30 amino acids in length and contains a sequence that is at least 70% homologous to VIKPLTKSYQGSGK. Also disclosed are methods of detecting the C-terminal domain truncation of mGluR1? by calpain, methods of inhibiting the C-terminal domain truncation of mGluR1? in a neuron, and methods of identifying a compound that inhibits the C-terminal domain truncation of mGluR1?.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: February 4, 2014
    Assignee: University of Southern California
    Inventors: Michel Baudry, Wei Xu
  • Methods of inhibiting calcineurin with ApoE analogs
    Patent number: 8629242
    Abstract: The present invention provides a method of modulating calcineurin activity in a cell by contacting the cell with at least one ApoE analog. Methods of treating various disorders associated with calcineurin activity using one or more ApoE analogs are also disclosed. In particular, the present invention provides a method of reducing demyelination and promoting remyelination in a subject. Methods of treating spinal cord or nerve injury in a subject are also described.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: January 14, 2014
    Assignee: Cognosci, Inc.
    Inventors: Michael P. Vitek, Feng-Qiao Li
  • Composition and method for making oligo-benzamide compounds
    Patent number: 8618324
    Abstract: The present invention includes compound compositions and methods of making compounds that include an oligo-benzamide compound having at least two optionally substituted benzamides.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: December 31, 2013
    Assignee: Board of Regents, The University of Texas System
    Inventor: Jung-Mo Ahn
  • Peptides having an ACE inhibiting effect
    Patent number: 8618249
    Abstract: Use of the tripeptide ITP and salts thereof for the preparation of a functional food angiotensin-converting enzyme inhibitor. Also provided is the use of the combination of tripeptide MAP and the tripeptide ITP and salts thereof as an angiotensin-converting enzyme inhibitor in functional foods.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: December 31, 2013
    Assignee: DSM IP Assets B.V.
    Inventor: Christianus Jacobus van Platerink
  • Stabilized pharmaceutical peptide compositions
    Patent number: 8614181
    Abstract: Method for increasing the shelf-life of a pharmaceutical composition for parenteral administration comprising a glucagon-like peptide which is prepared from a peptide product that has been subjected to treatment at a pH above neutral pH.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: December 24, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Claus Juul-Mortensen, Dorte Kot Engelund
  • Modified globin proteins with altered electron transport pathway
    Patent number: 8609814
    Abstract: The present invention relates to a modified porphyrin-based oxygen-carrying protein, such as haemoglobin, which has been found, in its unmodified state to have a low affinity site of electron transfer and a high affinity electron transfer between a reductant and ferryl haem iron via one or more protein amino acids. The invention provides such proteins that comprise a modification to enhance this pathway.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: December 17, 2013
    Assignee: University of Essex Enterprises Limited
    Inventors: Christopher Eric Cooper, Michael Thomas Wilson, Brandon Jon Reeder
  • Prodrug anti-cancer therapy
    Patent number: 8609813
    Abstract: Compositions and methods for inhibiting the growth of cancer cells are provided. The cancer cells, the growth of which is inhibited, have constitutively active Abl tyrosine kinase activity due to a t(9;22)(q34;q11) translocation which results in expression of a chimeric Bcr-Abl protein which has constitutively active Abl tyrosine kinase activity that is believed to play an important role in leukemogenesis. The compositions include a modified protein kinase C(PKC) which has an Abl tyrosine kinase target motif. The methods involve administering the modified PCK to an individual to inhibit the growth of cancer cells that have Abl tyrosine kinase activity.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: December 17, 2013
    Assignee: Health Research Inc.
    Inventors: Kelvin Lee, Louise Carlson
  • Glycomacropeptide medical foods for nutritional management of phenylketonuria and other metabolic disorders
    Patent number: 8604168
    Abstract: Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: December 10, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Denise M. Ney, Mark R. Etzel
  • Peptide pharmaceutical for oral delivery
    Patent number: 8592366
    Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: November 26, 2013
    Assignee: Enteris Biopharma, Inc.
    Inventors: William Stern, Angelo P. Consalvo
  • Polymer-factor IX moiety conjugates
    Patent number: 8586711
    Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: November 19, 2013
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Gayle Stephenson
  • Method for cancer immunotherapy
    Patent number: 8575308
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: November 5, 2013
    Assignees: International Institute of Cancer Immunology, Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Toshio Nishihara, Masashi Gotoh
  • Methods for regulating inflammatory mediators and peptides for useful therein
    Patent number: 8563689
    Abstract: The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from the vesicles or granules in the inflammatory cells in a subject with a chronic inflammatory disease. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. MANS peptide and active fragments thereof are useful in such methods.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: October 22, 2013
    Assignees: North Carolina State University, Biomarck Pharmaceuticals, Ltd.
    Inventors: Shuji Takashi, Indu Parikh, Kenneth B. Adler, Linda D. Martin, Yuehua Li
  • L-Threonine derivatives of high therapeutic index
    Patent number: 8563776
    Abstract: The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: October 22, 2013
    Assignee: Signature R&D Holdings, LLC
    Inventor: V. Ravi Chandran
  • Fatty acid formulations and oral delivery of proteins and peptides, and uses thereof
    Patent number: 8563685
    Abstract: Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: October 22, 2013
    Assignee: Biocon Limited
    Inventors: Balasingam Radhakrishnan, Diti Aggarwal, Michelle Ferro, Kenneth D. James, Navdeep B. Malkar, Mark A. Miller, Leo Pavliv, Karen Polowy, Monica Puskas, Nnochiri N. Ekwuribe